Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation

The recruitment of T lymphocytes during diseases such as rheumatoid arthritis is regulated by stimulation of the chemokine receptors expressed by these cells. This study was designed to assess the potential of a CXCR3-specific small-molecule agonist to inhibit the migration of activated human T cells toward multiple chemokines. Further experiments defined the molecular mechanism for this anti-inflammatory activity. Analysis in vitro demonstrated agonist induced internalization of both CXCR3 and other chemokine receptors coexpressed by CXCR3+ T cells. Unlike chemokine receptor-specific antagonists, the CXCR3 agonist inhibited migration of activated T cells toward the chemokine mixture in synovial fluid from patients with active rheumatoid arthritis. A humanized mouse air-pouch model showed that intravenous treatment with the CXCR3 agonist prevented inflammatory migration of activated human T cells toward this synovial fluid. A potential mechanism for this action was defined by demonstration that the CXCR3 agonist induces receptor cross-phosphorylation within CXCR3-CCR5 heterodimers on the surface of activated T cells. This study shows that generalized chemokine receptor desensitization can be induced by specific stimulation of a single chemokine receptor on the surface of activated human T cells. A humanized mouse model was used to demonstrate that this receptor desensitization inhibits the inflammatory response that is normally produced by the chemokines present in synovial fluid from patients with active rheumatoid arthritis.

[1]  Jakob S. Jensen,et al.  Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. , 1999, The Journal of clinical investigation.

[2]  J. Isaacs,et al.  A Non-Glycosaminoglycan-Binding Variant of CC Chemokine Ligand 7 (Monocyte Chemoattractant Protein-3) Antagonizes Chemokine-Mediated Inflammation1 , 2005, The Journal of Immunology.

[3]  E. Hoster,et al.  Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease , 2010, Inflammatory bowel diseases.

[4]  R. Doms,et al.  Antigenically Distinct Conformations of CXCR4 , 2001, Journal of Virology.

[5]  J. Michel,et al.  Smooth muscle cell modulation and cytokine overproduction in varicose veins. An in situ study , 2001, The Journal of pathology.

[6]  M. I. Christie,et al.  Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI‐74330, using a murine CXCR3 internalization assay , 2007, British journal of pharmacology.

[7]  I. D. de Esch,et al.  CXCR3 antagonists: quaternary ammonium salts equipped with biphenyl- and polycycloaliphatic-anchors. , 2011, Bioorganic & medicinal chemistry.

[8]  J. Sprent,et al.  Normal T cell homeostasis: the conversion of naive cells into memory-phenotype cells , 2011, Nature Immunology.

[9]  Johan Kuiper,et al.  CXCR3 Antagonist NBI-74330 Attenuates Atherosclerotic Plaque Formation in LDL Receptor–Deficient Mice , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[10]  Simi Ali,et al.  Anti-inflammatory therapy by intravenous delivery of non-heparan sulfate-binding CXCL12 , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  Ashok Kumar,et al.  CXCR4 physically associates with the T cell receptor to signal in T cells. , 2006, Immunity.

[12]  Simi Ali,et al.  T cell extravasation: Demonstration of synergy between activation of CXCR3 and the T cell receptor , 2009, Molecular immunology.

[13]  R. Koenen,et al.  Heterophilic chemokine receptor interactions in chemokine signaling and biology. , 2011, Experimental cell research.

[14]  Simi Ali,et al.  An apparent paradox: chemokine receptor agonists can be used for anti-inflammatory therapy. , 2007, Molecular immunology.

[15]  Simi Ali,et al.  Chemokine-mediated inflammation: Identification of a possible regulatory role for CCR2. , 2007, Molecular immunology.

[16]  E. McDonagh,et al.  The Chemokine Receptor CXCR3 Is Degraded following Internalization and Is Replenished at the Cell Surface by De Novo Synthesis of Receptor1 , 2008, The Journal of Immunology.

[17]  T. Williams,et al.  The attraction of chemokines as a target for specific anti‐inflammatory therapy , 2006, British journal of pharmacology.

[18]  J. Flier,et al.  Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation , 2001, The Journal of pathology.

[19]  D. Willoughby,et al.  Increased inflammatory reactivity in newly formed lining tissue , 1983, The Journal of pathology.

[20]  R. Fairchild,et al.  CXCR3 Antagonism Impairs the Development of Donor-Reactive, IFN-&ggr;-Producing Effectors and Prolongs Allograft Survival , 2009, Transplantation.

[21]  S. Momohara,et al.  Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients , 2008, The FEBS journal.

[22]  A. Koch,et al.  Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. , 2001, Arthritis and rheumatism.

[23]  C. R. Bagnell,et al.  Endothelium specific Weibel-Palade bodies in a continuous human cell line, EA.hy926 , 1990, In Vitro Cellular & Developmental Biology.

[24]  P. Romero,et al.  Use of phycoerythrin and allophycocyanin for fluorescence resonance energy transfer analyzed by flow cytometry: advantages and limitations. , 2002, Cytometry.

[25]  Maria L Webb,et al.  Identification of CXCR3 receptor agonists in combinatorial small-molecule libraries. , 2006, Biochemical and biophysical research communications.

[26]  M. Haniffa,et al.  Regulatory T-Cell Suppression of CD8+ T-Cell-Mediated Graft-Versus-Host Reaction Requires Their Presence During Priming , 2009, Transplantation.

[27]  M. Schwarz,et al.  Anti-chemokine small molecule drugs: a promising future? , 2010, Expert opinion on investigational drugs.

[28]  M. Oppermann,et al.  G Protein-coupled Receptor Kinases Promote Phosphorylation and β-Arrestin-mediated Internalization of CCR5 Homo- and Hetero-oligomers* , 2005, Journal of Biological Chemistry.

[29]  N. Ward,et al.  Kinetic analysis of protein kinase C inhibition by staurosporine: evidence that inhibition entails inhibitor binding at a conserved region of the catalytic domain but not competition with substrates. , 1992, Molecular pharmacology.

[30]  D. Greiner,et al.  Non‐obese diabetic–recombination activating gene‐1 (NOD–Rag 1 null) interleukin (IL)‐2 receptor common gamma chain (IL 2 rγnull) null mice: a radioresistant model for human lymphohaematopoietic engraftment , 2008, Clinical and experimental immunology.

[31]  R. Horuk,et al.  Chemokine receptor antagonists: overcoming developmental hurdles , 2009, Nature Reviews Drug Discovery.

[32]  S. Bromley,et al.  Orchestrating the orchestrators: chemokines in control of T cell traffic , 2008, Nature Immunology.

[33]  Anthony E. Klon,et al.  Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3 , 2012, British journal of pharmacology.

[34]  J. Kirby,et al.  Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo , 2007, British Journal of Cancer.

[35]  Xiaoming Xie,et al.  Technique for Generating Three-Dimensional Alignments of Multiple Ligands from One-Dimensional Alignments , 2008, J. Chem. Inf. Model..

[36]  Ariane L. Jansma,et al.  Characterization of the Chemokine CXCL11-Heparin Interaction Suggests Two Different Affinities for Glycosaminoglycans* , 2010, The Journal of Biological Chemistry.

[37]  T. Schall,et al.  Overcoming hurdles in developing successful drugs targeting chemokine receptors , 2011, Nature Reviews Immunology.

[38]  D. Irimia,et al.  Subsets of human CD4+ regulatory T cells express the peripheral homing receptor CXCR3 , 2011, European journal of immunology.

[39]  Albert Zlotnik,et al.  Pharmacological Characterization of CXC Chemokine Receptor 3 Ligands and a Small Molecule Antagonist , 2005, Journal of Pharmacology and Experimental Therapeutics.

[40]  G. Calandra,et al.  Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.